BioCentury
ARTICLE | Company News

Actimis Pharmaceuticals, Boehringer Ingelheim deal

June 23, 2008 7:00 AM UTC

Boehringer will acquire Actimis in a structured buyout tied to the development of Actimis’ lead compound, AP768. The antagonist of chemoattractant receptor-homolog on Th2 cells ( CRTH2) is in Phase I...